Iron-Induced Cardiac Damage: Role of Apoptosis and Deferasirox Intervention
Open Access
- 14 October 2010
- journal article
- research article
- Published by American Society for Pharmacology & Experimental Therapeutics (ASPET) in The Journal of pharmacology and experimental therapeutics
- Vol. 336 (1), 56-63
- https://doi.org/10.1124/jpet.110.172668
Abstract
Excess cardiac iron levels are associated with cardiac damage and can result in increased morbidity and mortality. Here, we hypothesize that elevations in tissue iron can activate caspase-dependent signaling, which leads to increased cardiac apoptosis and fibrosis, and that these alterations can be attenuated by iron chelation. Using an iron-overloaded gerbil model, we show that increased cardiac iron is associated with reduced activation of Akt (Ser473 and Thr308), diminished phosphorylation of the proapoptotic regulator Bad (Ser136), and an increased Bax/Bcl-2 ratio. These iron-overload-induced alterations in Akt/Bad phosphorylation and Bax/Bcl-2 ratio were coupled with increased activation of the downstream caspase-9 (40/38- and 17-kDa fragments) and apoptosis executioner caspase-3 (19- and 17-kDa fragments), which were accompanied by evidence of elevated cytoskeletal α-fodrin cleavage (150- and 120-kDa fragments), discontinuity of myocardial membrane dystrophin immunoreactivity, increases in the number of terminal deoxynucleotidyl transferase dUTP nick-end labeling (TUNEL)-positive cells (nucleic DNA fragmentation), and cardiac fibrosis. We demonstrate that the administration of deferasirox, a tridentate iron chelator, is associated with diminished tissue iron deposition, attenuated activation of caspases, reduced α-fodrin cleavage, improved membrane integrity, decreased TUNEL reactivity, and attenuated cardiac fibrosis. These results suggest that the activation of caspase-dependent signaling may play a role in the development of iron-induced cardiac apoptosis and fibrosis, and deferasirox, via a reduction in cardiac tissue iron levels, may be useful for decreasing the extent of iron-induced cardiac damage.Keywords
This publication has 39 references indexed in Scilit:
- Deferasirox Decreases Age-Associated Iron Accumulation in the Aging F344XBN Rat Heart and LiverCardiovascular Toxicology, 2010
- Deferasirox removes cardiac iron and attenuates oxidative stress in the iron‐overloaded gerbilAmerican Journal of Hematology, 2009
- Iron Causes Interactions of TAK1, p21ras, and Phosphatidylinositol 3-Kinase in Caveolae to Activate IκB Kinase in Hepatic MacrophagesJournal of Biological Chemistry, 2007
- The impact of iron overload and its treatment on quality of life: results from a literature reviewHealth and Quality of Life Outcomes, 2006
- Apoptotic stress pathway activation mediated by iron on endothelial cells in vitroNephrology Dialysis Transplantation, 2006
- Survival and Complications in ThalassemiaAnnals of the New York Academy of Sciences, 2005
- Cardiac Fibrosis as a Cause of Diastolic DysfunctionHerz, 2002
- Apoptosis is prevented by administration of superoxide dismutase in dogs with reperfused myocardial infarctionBasic Research in Cardiology, 1998
- Improvement of postischemic myocardial function and metabolism induced by administration of deferoxamine at the time of reflow: the role of iron in the pathogenesis of reperfusion injury.Circulation, 1987
- A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye bindingAnalytical Biochemistry, 1976